ClinicalTrials.gov
ClinicalTrials.gov Menu

The Study of Atherosclerosis With Ramipril and Rosiglitazone

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00140647
Recruitment Status : Completed
First Posted : September 1, 2005
Last Update Posted : August 25, 2008
Sponsor:
Collaborator:
Heart and Stroke Foundation of Ontario
Information provided by:
Gerstein, Hertzel, MD

Brief Summary:
The purpose of this study is to determine if ramipril and/or rosiglitazone retard the progression of atherosclerosis as evaluated by serial carotid intermedial thickness measurements.

Condition or disease Intervention/treatment Phase
Atherosclerosis Impaired Glucose Tolerance Isolated Impaired Fasting Glucose Cardiovascular Disease Drug: Ramipril Drug: Rosiglitazone Phase 3

Detailed Description:

STARR is a multi-centre, international, randomized controlled clinical trial with a 2x2 factorial design, that will evaluate the effects of ramipril and of rosiglitazone on atherosclerosis progression, as determined by B-mode carotid ultrasound (US). It is designed as a substudy of DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medications) Trial. The study is designed to enroll 1,200 study participants and follow is proposed for an average of 3.75 years.

SIGNIFICANCE OF THE PROPOSED RESEARCH: With regards to ramipril this study will provide important mechanistic data regarding potential benefits of ACE inhibitor therapy on atherosclerosis and by inference in reducing CV risk in a lower risk younger population than studied in previous trials. In this population a clinical outcome trial focusing primarily on CV events would be difficult to conduct due to the expected fairly low event rate. If the study on atherosclerosis is positive, this may provide a rational for therapy in this subset of patients without overt CVD or diabetes, but with impaired glucose tolerance or impaired fasting glucose.


Study Type : Interventional  (Clinical Trial)
Enrollment : 1200 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: The Study of Atherosclerosis With Ramipril and Rosiglitazone
Study Start Date : July 2001
Actual Study Completion Date : July 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Atherosclerosis
U.S. FDA Resources




Primary Outcome Measures :
  1. The change of the mean maximum carotid intimal medial thickness (IMT)evaluated across 12 segments involving the left and right common carotid, bifurcation and internal carotid arteries.

Secondary Outcome Measures :
  1. The change over time in the mean IMT across the common carotid far wall IMT of the right and the left carotid arteries.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • impaired glucose tolerance (FPG < 7 mmol/L or 126 mg/dL & 2hr PG between 7.8-11.0 mmol/l [140-199 mg/dl] after a 75 g OGTT
  • impaired glucose tolerance (FPG≥ 6.1 mmol/l [110 mg/dl]) and no diabetes (i.e. a FPG < 7.0 mmol/l [126 mg/dl])
  • a technically adequate baseline carotid ultrasound examination

Exclusion Criteria:

  • current use of an ACE-inhibitor (ACE-I) or thiazolidinedione (TZD)
  • known hypersensitivity to ACE-I
  • prior use of anti-diabetic medications 9with the exception of during pregnancy)
  • use of systemic glucocorticoids or niacin
  • congestive heart failure or EF < 40%
  • existing cardiovascular disease (previous MI, stroke, angina, uncontrolled hypertension)
  • diabetes
  • renal or hepatic disease
  • major illness
  • use of another experimental drug
  • pregnant or unwilling to use reliable contraception
  • major psychiatric disorder
  • diseases that affect glucose tolerance
  • unwillingness to be randomized or sign informed consent
  • known uncontrolled substance abuse
  • inability to communicate with research staff

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00140647


Sponsors and Collaborators
Gerstein, Hertzel, MD
Heart and Stroke Foundation of Ontario
Investigators
Principal Investigator: Eva Lonn, MD McMaster University

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00140647     History of Changes
Other Study ID Numbers: STARR
First Posted: September 1, 2005    Key Record Dates
Last Update Posted: August 25, 2008
Last Verified: August 2008

Keywords provided by Gerstein, Hertzel, MD:
atherosclerosis
carotid artery
ramipril
rosiglitazone
impaired glucose tolerance
impaired fasting glucose
diabetes prevention

Additional relevant MeSH terms:
Cardiovascular Diseases
Atherosclerosis
Glucose Intolerance
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Hyperglycemia
Glucose Metabolism Disorders
Metabolic Diseases
Rosiglitazone
Ramipril
Hypoglycemic Agents
Physiological Effects of Drugs
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents